Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …

Cell death plays two major complementary roles in T cell biology: mediating the removal of
cells that are targeted by T cells and the removal of T cells themselves. T cells serve as …

Adoptive cell transfer against solid tumors faces challenges to overcome tumor
microenvironment (TME), which plays as a physical barrier and provides immuno …

Chimeric antigen receptor (CAR) T cells have shown remarkable success in treating
hematologic cancers. However, this efficacy has yet to translate to treatment in solid tumors …

Limited therapeutic options exist for the treatment of patients with triple negative breast
cancer (TNBC). Neoadjuvant chemotherapy is currently the standard of care treatment in the …

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients
with non-small cell lung cancer (NSCLC). Although some patients can experience important …

One of the current greatest challenges of Chagas disease is the establishment of biomarkers
to assess the efficacy of drugs in a short period of time. In this context, the reactivity of sera …

Perforin is an indispensable effector protein of primary cytotoxic lymphocytes (CTL or NK
cells) that typically defend the host against virus infection, or gene-modified (chimeric …

Antigen peptides and adjuvants have been extensively investigated for cancer
immunotherapy, and they are expected to elicit specific immune responses for cancer …

Expression of the adenovirus E1A oncogene sensitizes tumor cells to innate immune
rejection by NK cells. This increased NK sensitivity is only partly explained by an E1A …